Skip to main content

Schizophrenia

Featured Article
Mark Munger, PharmD, explains why careful observation of patients being treated with ACEi based on salt classification may be warranted in patients with active symptoms or with a family history of…
“Unfortunately, we did not achieve a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score in this study,” said Acadia Pharmaceuticals president Serge…

Insights

Carmela Benson, director, real world value & evidence, Janssen Scientific Affairs, LLC, discusses recent research that examined Schizophrenia Population Health Management among adults in order to better understand how population health decision…
Mark Munger, PharmD, explains why careful observation of patients being treated with ACEi based on salt classification may be warranted in patients with active symptoms or with a family history of schizophrenia.
Formulary decisions for treating schizophrenia must balance saving costs and improving medication  adherence without contributing to the disease burden.
Managing Mental Health is a 3-part series dedicated to exploring the challenges managed care professionals face regarding the treatment of mental health illnesses, with a specific focus on dementia, schizophrenia, and depression.
Back to Top